To read the full version of this content please select one of the options below:

Recent legal and policy developments affecting the EU pharmaceutical business environment

Alan Earl‐Slater (Director of European Research, Oxford Health Economics, Oxford, UK and Senior Lecturer in Health Economics, Department of Medicines Management, University of Keele, Staffordshire, UK)

European Business Review

ISSN: 0955-534X

Article publication date: 1 December 1997

Abstract

Aims to identify and explore recent legal and policy developments affecting the EU pharmaceutical business environment. Areas addressed are: the declaration of industry policy from the European Commission and the MEPs’ recent response to this, drug licensing, member state trade in pharmaceuticals, price and profit controls, and state aid. States none of these areas are quite so mutually exclusive, and that there is more to the EU pharmaceutical industry than just the drugs it provides and while there is a growing trend towards a single EU market in pharmaceuticals it is highly unlikely that a single market will be achieved in the next decade. Argues that EU policies must facilitate a strong, profitable, pharmaceutical industry. Regardless of how successful the EU pharmaceutical industry is, it is still behind the USA and looks likely to remain so. The EU as a pharmaceutical area is beginning to be eclipsed by newly‐emerging areas in the Fast East and whether or not EU governments have formal, explicit pharmaceutical industry policy, these governments will still affect the pharmaceutical environment. Concludes that the fundamental questions of any industrial policy must be carefully addressed.

Keywords

Citation

Earl‐Slater, A. (1997), "Recent legal and policy developments affecting the EU pharmaceutical business environment", European Business Review, Vol. 97 No. 6, pp. 267-278. https://doi.org/10.1108/09555349710189978

Publisher

:

MCB UP Ltd

Copyright © 1997, MCB UP Limited